Journals / Journal of Neurological Sciences (Turkish) / 2016 / Cilt: 33 - Sayı: 3

Course of Migraine with Aura: A Follow-up Study

Pages
433–442
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our findings might guide clinicians to reveal treatment goals and to develop effective treatment strategies

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Migraine has a prevalence of between 10-13% worldwide and one-third of the migraine patients complaint aura symptoms.
📊
Key Findings & Data:Methods: The data of 230 patients were obtained from an electronic headache database retrospectively as a part of the Turkish Headache Database Project, and a latent growth mixture model was used to assess the variables.
💡
Conclusion & Impact:Our findings might guide clinicians to reveal treatment goals and to develop effective treatment strategies
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Migraine has a prevalence of between 10-13% worldwide and one-third of the migraine patients complaint aura symptoms. However, the current understanding of the course of migraine with aura still remains uncertain. We aimed to determine the baseline and the time course characteristics of migraine with aura and to assess the evolution of headache frequency, duration and intensity. Methods: The data of 230 patients were obtained from an electronic headache database retrospectively as a part of the Turkish Headache Database Project, and a latent growth mixture model was used to assess the variables. The frequency (low, medium, and high), duration (short, long) and severity (mild, moderate, and severe) of headaches were analyzed with a three-group model, a two-group-model, and a second three-group model, respectively. The probabilities for each of the subgroups were estimated using the latent growth mixture models. Results: Unilaterality and dizziness were more likely to be observed in the moderate severity group than the mild severity group (odds ratio [OR]: 3.146, p = 0.007; OR: 2.637, p = 0.047) and vomiting was a rare symptom in the medium group (OR: 0.467, p = 0.017). Within six months follow-up assessments, there were significant recovery rates in terms of headache frequency, duration, and severity (68%, 65%, and 56%, respectively). Conclusion: Our preliminary results support the importance of using longitudinal studies to reveal the course of migraine. Our findings might guide clinicians to reveal treatment goals and to develop effective treatment strategies

Özet

Migren prevalansı tüm dünyada %10-13 olarak bildirilmektedir ve hastaların üçte biri aura tarif etmektedirler. Fakat auralı migren seyri ile ilgili bilgilerimiz halen kısıtlıdır. Bu çalışmada auralı migren başlangıç ve takip özelliklerinin saptanması ve başağrısı sıklığı, süresi ve şiddetinin takip süresince değişiminin incelenmesi amaçlandı. Metod: Türkiye Başağrısı Veritabanı Projesi kapsamında oluşturulan elektronik veritabanı retrospektif olarak tarandı. Çalışmaya toplam 230 auralı migren hastası dahil edildi ve değişkenlerin zaman içerisindeki seyrinin belirlenmesi için latent growth mixture modeli kullanıldı. Başağrısı frekansı (düşük, orta, yüksek), süresi (kısa, uzun), ve şiddeti (hafif, orta, şiddetli) sırası ile üç grup, iki grup ve üç grupta model oluşturularak incelendi. Tüm alt grupların olasılıkları latent growth mixture modeli kullanılarak hesaplandı. Sonuçlar: Unilateral başağrısı ve dizziness orta şiddette başağrılı grupta daha sık gözlendi (odds ratio [OR]: 3.146, p = 0.007; OR: 2.637, p = 0.047) ve kusma orta şiddetli başağrısı grubunda nadir bir semptomdu (OR: 0.467, p = 0.017). Takipler süresi içerisinde başağrısı sıklığı, süresi ve şiddetinde belirgin düzelme izlendi (%68, %65, ve %56 sırası ile). Tartışma: Bu ön çalışmanın sonuçları migren seyrinin belirlenmesinde izlem çalışmalarının önemini desteklemektedir. Bulgularımız klinisyenlerin etkin tedavi stratejileri geliştirmeleri ve tedavi amaçlarının belirlemelerinde yardımcı olacağını düşünmekteyiz

🔖

Cite This Article

TAŞDELEN, B., ULUDÜZ, D., YALIN, O. Ö., TÜRKEGÜN, M., ÖZGE, A. (2022). Course of Migraine with Aura: A Follow-up Study. Journal of Neurological Sciences (Turkish), Cilt: 33 - Sayı: 3, 433–442. https://ajindex.com/articles/564877

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Balottin U, Borgatti R, Zamrino CA, Lansi G. Clinical characteristics and long-term outcome of migraine with aura in children and adolescents. Dev Med Child Neurol 1997; 39(1): 26-30.
  2. Bigal ME, Lipton RB. The Prognosis of migraine. Curr Opin Neurol 2008; 21(3): 301- 308. Bolay H. The first phase of a migraine attack resides in the cortex. J Neural Transm 2012; 119(5): 569-574.
  3. Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, Lipton RB. Chronic migraine sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 2012; 52(10): 1456-1470.
  4. Cologno D, Torelli P, Manzoni GC. Possible predictive factors in the prognosis of migraine with aura. Cephalalgia 1999; 19(9): 824-830.
  5. Eriksen MK, Thomsen LL, Russell MB. Prognosis of migraine with aura. Cephalalgia 2004; 24(1): 18-22.
  6. Ertas M, Baykan B, Orhan EK, Zarifoglu M, Karli N, Saip, S, Siva A. One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults. Headache 2012; 13(2): 147- 157. Etminan M, Takkouche B, Isorna FC, Samii A. (2005). Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 2005; 330: 63. Gudmundsson LS, Scher AI, Aspelund T, Eliasson JH, Johannsson M, Thorgeirsson G, Gudnason V. Migraine with aura and risk of cardiovascular and all cause mortality in men and women: prospective cohort study. BMJ 2010; 341. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, (beta version). Cephalalgia 2013; 33(9): 629-808. Headache Classification Committee of the International International Disorders, 2nd Edition. Cephalalgia 2004; 24: 1-160.
  7. Society. of Headache Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol 2008; 7(4): 354-361.
  8. Jones BL, Nagin DS, Roeder KA. SAS procedure based on mixture models for estimating development trajectories. Sociol Methods Res 2001; 29: 374-393.
  9. Kelman L, Tanis D. The relationship between migraine pain and other associated symptoms. Cephalalgia 2006; 26(5): 548-553.
  10. Kurth T, Gaziano JM, Cook NR, Logroscin G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. Jama 2006; 296(3): 283-291.
  11. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2012; 41(7): 646-657. Lyngbe